12,19-02





 \boxtimes

Other:

ROCKET NO.: CELL-0113

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Applicati Langham, Et A Serial No.: 09/8 Filing Date: Ju For: Squaric	l. 399,488	Confirmation No.: 2595 Group Art Unit: 1624 Examiner: T.C. McKenzie	TECH CENTER 10001-
		EXPRESS MAIL LABEL NO: EV 16 DATE OF DEPOSIT: December 18, 2	
		EATPOOUTJSTAZ	
Box NON AF	-FEE)
Assistant Comm Washington DC	issioner for Patents 20231		
Sir:		•	
	REPLY T	RANSMITTAL LETTER	
Transmit	ted herewith for filing	in the above-identified patent applicatio	on is:
☐ A Prelim	inary Amendment.		

An Amendment Responsive to the Office Action Dated July 24, 2002.

An Amendment Supplemental to the Paper filed

DOCI	ET NO.: CELL-0113 -2- PATENT						
	Applicant(s) has previously claimed small entity status under 37 CFR § 1.27.						
	Applicant(s) by its/their undersigned attorney, claims small entity status under 37 CFR § 1.27 as:						
	an Independent Inventor						
	a Small Business Concern						
	a Nonprofit Organization						
	This application is no longer entitled to small entity status. It is requested that this be noted in the files of the U.S. Patent and Trademark Office.						
	Loss of Entitlement Enclosed						
	Substitute Pages of the Specification are enclosed.						
	An Abstract is enclosed.						
	Sheets of Proposed Corrected Drawings are enclosed.						
	A Certified Copy of each of the following applications: is enclosed.						
	An Associate Power of Attorney is enclosed.						
	Information Disclosure Statement.						
	Attached Form 1449.						
·	A copy of each reference as listed on the attached Form PTO-1449 is enclosed herewith.	d					
	Appended Material as follows: Appendix A, "Molecular Variations Based of Isosteric Replacements" (7 pages); Appendix B, Grant & Hachk's Chemical Dictionary (3 pages); Appendix C Grant & Hachk's Chemical Dictionary (3 pages) Appendix D, Drug Report from the Investigational Drugs Database (5 pages) Appendix E, Ch 7 "Targeting VLA-4 Integrin Function: Potential Therapeuti Implications (10 pages) Chapter 8 "Role of the Intergrin α4β1 (VLA-4) in Inflammatory Disorders" (8 pages).	Appendix A, "Molecular Variations Based on s); Appendix B, Grant & Hachk's Chemical Grant & Hachk's Chemical Dictionary (3 pages); the Investigational Drugs Database (5 pages); VLA-4 Integrin Function: Potential Therapeutic					
	Other Material as follows:						

.

-

FEE CALCULATION

No Additional Fee is Due.

				SMALL ENTITY		NOT SMALL ENTITY	
	REMAINING AFTER AMENDMENT	HIGHEST PAID FOR	EXTRA	RATE	FEE	RATE	FEE
TOTAL CLAIMS	26	26 (20 MINIMUM)	0	\$9 EACH	\$	\$18 EACH	\$0
INDEP. CLAIMS	2	3 (3 MINIMUM)	0	\$42 EACH	\$	\$84 EACH	\$0
FIRST PRESENTATION OF MULTIPLE DEPENDENT			\$140	.\$	\$280	\$0	
ONE MONTH EXTENSION OF TIME			\$55	\$	\$110	\$0	
☐ TWO MONTH EXTENSION OF TIME				\$200	\$	\$400	\$400.00
☐ THREE MONTH EXTENSION OF TIME				\$460	\$	\$920	\$0
☐ FOUR MONTH EXTENSION OF TIME				\$720	\$	\$1440	\$0
☐ FIVE MONTH EXTENSION OF TIME				\$980	\$	\$1960	\$0
LESS ANY EXTENSION FEE ALREADY PAID				minus	(\$)	minus	(\$0)
☐ TERMINAL DISCLAIMER				\$55	\$	\$110	\$0
☐ OTHER FEE OR SURCHARGE AS FOLLOWS:							\$0
TOTAL FEE DUE					\$		\$400.00

- A check in the amount of \$\frac{\$400.00}{}\$ is attached. Please charge any deficiency or credit any overpayment to Deposit Account 23-3050.
- Petition is hereby made under 37 CFR § 1.136(a) (fees: 37 CFR § 1.17(a)(1)-(4) to extend the time for response to the Office Action of July 24, 2002 to and through December 24, 2002 comprising an extension of the shortened statutory period of two (2) month(s).
- The Commissioner is hereby requested to grant an extension of time for the appropriate length of time, should one be necessary, in connection with this filing or any future filing submitted to the U.S. Patent and Trademark Office in the above-identified application during the pendency of this application. The Commissioner is further authorized to charge any fees related to any such extension of time to Deposit Account 23-3050. This sheet is provided in duplicate.
- The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 23-3050. This sheet is provided in duplicate.

- Any additional filing fees required, including fees for the presentation of extra claims under 37 CFR § 1.16.
- Any additional patent application processing fees under 37 CFR § 1.17 or 1.20(d).

SHOULD ANY DEFICIENCIES APPEAR with respect to this application, including deficiencies in payment of fees, missing parts of the application or otherwise, the U.S. Patent and Trademark Office is respectfully requested to promptly notify the undersigned.

Date: December 18, 2002

Jane F. Inglese

Registration No. 48,444

Woodcock Washburn LLP One Liberty Place - 46th Floor Philadelphia PA 19103 Telephone: (215) 568-3100

Telephone: (215) 568-3100 Facsimile: (215) 568-3439

© 2002 WW